Clinical outcomes in Chinese patients with long lesion or small vessel or multivessel disease receiving XIENCE V everolimus-eluting stent: 6-month results from the SEEDS study

摘要：

Background The efficacy and safety of XIENCE V(R) everolimus-eluting coronary stems (XIENCE V, Abbott Vascular,Santa Clara, CA, USA) have been demonstrated in pre-marketing and post-marketing studies with low rates of target lesion revascularization (TLR), major cardiac adverse events and stem thrombosis (ST).However, these results were mainly obtained in populations of European heritage.SEEDS is the first study in China to evaluate XIENCE V”s performance in Chinese patients with complex lesions.

作者: XU Bo YANG Yue-jin HAN Ya-ling LI Bao LIU Qiang ZHU Guo-ying CUI Jun-yu LI Lang LU Shu-zheng

作者单位: Fu Wai Hospital National Center for Cardiovascular Diseases,Beiing 100037,China Shenyang Northern Hospital,Shenyang,China Shanxi Provincial Cardiovascular Institute,Taiyuan,China Shenzhen Sun Yat-Sen Cardiovascular Hospital,Shenzhen,China Wuhan Asia Heart Hospital,Wuhan,China Beijing Military General Hospital Beijing,China The First Affiliated Hospital of Guangxi Medical University,Nanning,China Affiliated Anzhen Hospital of Capital Medical University,Beijing,China

会议类型: 国内会议

会议名称: 第11届中国介入心脏病学大会

会议地点: 北京

会议语种:英文

页码: 6-7

在线出版日期: 2013-03-20（万方平台首次上网日期，不代表论文的发表时间）